Polycystic ovarian syndrome (PCOS) is the leading cause of anovulatory
infertility and is a heterogenous condition associated with a range of reproductive and metabolic impairments. While its etiology remains unclear,
hyperandrogenism and impaired
steroid negative feedback have been identified as key factors underpinning the development of PCOS-like features both clinically and in animal models. We tested the hypothesis that
androgen signaling in
kisspeptin-expressing neurons, which are key drivers of the neuroendocrine reproductive axis, is critically involved in PCOS pathogenesis. To this end, we used a previously validated
letrozole (LET)-induced hyperandrogenic mouse model of PCOS in conjunction with Cre-lox technology to generate female mice exhibiting
kisspeptin-specific deletion of
androgen receptor (KARKO mice) to test whether LET-treated KARKO females are protected from the development of reproductive and metabolic PCOS-like features. LET-treated mice exhibited
hyperandrogenism, and KARKO mice exhibited a significant reduction in the coexpression of
kisspeptin and
androgen receptor mRNA compared to controls. In support of our hypothesis, LET-treated KARKO mice exhibited improved estrous cyclicity, ovarian morphology, and
insulin sensitivity in comparison to LET-treated control females. However, KARKO mice were not fully protected from the effects of LET-induced
hyperandrogenism and still exhibited reduced corpora lutea numbers and increased
body weight gain. These data indicate that increased
androgen signaling in
kisspeptin-expressing neurons plays a critical role in PCOS pathogenesis but highlight that other mechanisms are also involved.